8080-01

CASE 4-32907A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

971832721 US Express Mail Label Number

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1614

FORENZO ET AL.

Kudla, Joseph S

APPLICATION NO: 10/549,249 FILED: NOVEMBER 10, 2005

FOR: PHARMACEUTICAL COMPOSITION COMPRISING 5-METHYL-2-

2'(CHLORO-6'-FLUOROANILINO) PHENYLACETIC ACID

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

PETITION FOR EXTENSION OF TIME

Sir:

The Office Action of April 14, 2008 has a shortened statutory time set to expire on July 14, 2008. A three-month extension is hereby requested pursuant to 37 CFR §1.136(a).

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$1110 for payment of the extension fee. An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.17 which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

Attorney for Applicants

Reg. No. 47,487

Novartis Pharmaceuticals Corp. Patents Pharma One Health Plaza, Building 104 East Hanover, NJ 07936-1080

Phone No. (862) 778-1202

October 7, 2008

10/08/2008 HVU0NG1 00000033 190134 10549249

01 FC:1253 1110.00 DA



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV97183272145
Express Mail Label Number

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1614

FORENZO ET AL.

Kudla, Joseph S

APPLICATION NO: 10/549,249 FILED: NOVEMBER 10, 2005

FOR: PHARMACEUTICAL COMPOSITION COMPRISING 5-METHYL-2-

2'(CHLORO-6'-FLUOROANILINO) PHENYLACETIC ACID

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

PETITION FOR EXTENSION OF TIME

Sir:

The Office Action of April 14, 2008 has a shortened statutory time set to expire on July 14, 2008. A three-month extension is hereby requested pursuant to 37 CFR §1.136(a).

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$1110 for payment of the extension fee. An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.17 which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

Novartis Pharmaceuticals Corp. Patents Pharma One Health Plaza, Building 104 East Hanover, NJ 07936-1080

Date: October 7, 2008

ปennifer C. Chapman Attorney for Applicants

Reg. No. 47,487

Phone No. (862) 778-1202